Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- New therapies change landscape of care for patients with HF Erik Swain
-
- 2015: A year of important advances; challenges ahead Carl J. Pepine, MD, MACC
- FDA panel votes against new indication for ezetimibe, combination therapy
- AHA: Women with type 2 diabetes have higher CHD risk than men
- More than half of US physicians experiencing professional burnout
- Multivessel revascularization improves outcomes, quality of life in patients with STEMI
- Overweight, obesity increase risk for sudden cardiac death in women
- Premenstrual syndrome may confer elevated risk for hypertension
- Robotic surgical mitral valve repair associated with high survival, few complications
-
- Society of Thoracic Surgeons: Use arteries rather than veins in CABG
- COSMIC-HF: Omecamtiv mecarbil safe, effective for patients with chronic HF
- Fifty-Fifty Study: Peer group support proves beneficial for CV health
- Highly walkable neighborhoods reduce incident hypertension by half
- IVUS guidance superior to angiography guidance for EES implantation in long lesions
- JUPITER update: Percent reduction of LDL relates to magnitude of risk reduction
- Miniature leadless pacemaker meets safety, efficacy goals at 6 months
- PRADA: Candesartan prevents LVEF decline in women treated for breast cancer
-
- Rivaroxaban antidote met all endpoints in phase 3 ANNEXA-R study
- RWISE: By most metrics, ranolazine fails to benefit patients with microvascular dysfunction
- VIDEO: CVD prevention looks promising with positive new data
- VIDEO: Novel DAPT score calculator could help resolve uncertainties around therapy duration
- VIDEO: Small increases to exercise capacity improve long-term CVD, mortality risk
- Meeting Update: Perspectives on major trials front and center at TCT Scientific Symposium
- Trial Scorecard: CATCH
- Trial Scorecard: CURRENT AS
-
- Trial Scorecard: DEBATE-ISR
- Trial Scorecard: MBC2
- Trial Scorecard: NEOLITH
- Trial Scorecard: PROACT-4
- Trial Scorecard: RWISE
- Trial Scorecard: TATORT-NSTEMI